Is Curis, Inc. (CRIS) a Buy, Sell, or Hold?
NASDAQ : CRIS
Curis, Inc.
$4.02 USD
-$0.39 (-8.84%)
- Volume
- 69.17K
- Average Volume
- 166.83K
- Market Capitalization
- $7.83M
- P/E Ratio
- -0.17
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $39.00
- Year Low
- $3.60
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.00
Company Overview
NASDAQ
James Dentzer
Biotechnology
Healthcare
CRIS
24
US
USD
Liquidity Metrics
0.11
1.00
1.00
1.00
0.00
Sales & Valuation
$9.44M
1.11
0.31
-0.27
-29.90
Profitability
-$11.6
-$7.58M
-299.66%
-299.66%
805.67%
-71.30%
P/E Metrics
-0.17
0.00
0.00
Analyst Price Target & Rating
2/5
18 Analysts
%
Financial Health Scores
-61.74
1/9
$27000.0
$29.69M
$16.98M
-$20.59M
Key Metrics (TTM)
-$5.83M
-0.83
0.28
1.00
805.67%
-259.95%
-543.80%
-369.51%
-63098 days
Company Executives
| Name | Title |
|---|---|
| Jonathan Zung | Chief Development Officer |
| Rachel Blasbalg | Senior Director of Human Resources |
| Nancy Soohoo | Vice President & General Counsel |
| Ahmed Hamdy | Chief Medical Officer |
| Mark W. Noel | Vice President of Technology Management & Intellectual Property |
| James E. Dentzer | President, Chief Executive Officer, Secretary, Treasurer & Director |
| Diantha Duvall | Chief Financial Officer and Principal Financial & Accounting Officer |
Poll Results
No votes yet today — be the first to share your view!
About Curis, Inc. (NASDAQ:CRIS) Stock
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 an ... d TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Curis Doses First Five Patients in TakeAim CLL Study
2026-07-30 08:00:00
LEXINGTON, Mass., July 30, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study in patients with Chronic Lymphocytic Leukemia (CLL).
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus
2026-07-24 14:03:48
On Wednesday, Curis Inc. (NASDAQ:CRIS) announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance.
2026-07-22 13:50:25
Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript
Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates
2026-07-22 13:04:16
Curis Inc. (NASDAQ:CRIS) on Wednesday announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance.
Curis Announces Positive Emavusertib Update
2026-07-22 07:00:00
Updated Clinical Data in PCNSL Increased Guidance on Year-End Data in CLL Company to Host Webcast at 8:30 a.m. ET LEXINGTON, Mass.
Curis Consents First Six Patients in TakeAim CLL Study
2026-07-06 09:30:00
LEXINGTON, Mass., July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study.
2026-06-26 10:00:00
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Rever
2026-06-26 09:42:00
Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company reaffirms guidance for dosing of initial five patients by end of July 2026 with data expected December 2026; Stockholders approve reverse stock split LEXINGTON, Mass., June 26, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that eleven clinical sites have been initiated and are now open for patient enrollment in its Phase 2 TakeAim CLL study evaluating emavusertib in combination with zanubrutinib in patients with Chronic Lymphocytic Leukemia.
Frequently Asked Questions
-
What is the current Curis, Inc. (CRIS) stock price?
-
Curis, Inc.(NASDAQ:CRIS) stock price is $4.02 in the last trading session. During the trading session, CRIS stock reached the peak price of $39 while $3.6 was the lowest point it dropped to. The percentage change in CRIS stock occurred in the recent session was --8.84% while the dollar amount for the price change in CRIS stock was -$0.39.
-
CRIS's industry and sector of operation?
-
The NASDAQ listed CRIS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CRIS?
-
Jonathan Zung | Chief Development Officer
Rachel Blasbalg | Senior Director of Human Resources
Nancy Soohoo | Vice President & General Counsel
Ahmed Hamdy | Chief Medical Officer
Mark W. Noel | Vice President of Technology Management & Intellectual Property -
How many employees does CRIS have?
-
Number of CRIS employees currently stands at 24. CRIS operates from Building C, Lexington, MA 02421, US.
-
Link for CRIS official website?
-
Official Website of CRIS is: https://www.curis.com
-
How do I contact CRIS?
-
CRIS could be contacted at phone #617 503 6500 and can also be accessed through its website. CRIS operates from Building C, Lexington, MA 02421, US.
-
How many shares of CRIS are traded daily?
-
The average number of CRIS shares traded daily for last 3 months was 166.83K.
-
What is the market cap of CRIS currently?
-
The market value of CRIS currently stands at $7.83M with its latest stock price at $4.02